Synthesis and evaluation of 7,8-dehydrorutaecarpine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease

European Journal of Medicinal Chemistry

Volumn 63, Issue , 2013, Pages 299-312

  He, Yan ^a   Yao, Pei Fen ^a   Chen, Shuo Bin ^a   Huang, Zhi Hong ^a   Huang, Shi Liang ^a   Tan, Jia Heng ^a   Li, Ding ^a   Gu, Lian Quan ^a   Huang, Zhi Shu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

7,8 Dehydrorutaecarpine derivatives; A aggregation; Acetylcholinesterase; Alzheimer's disease; Antioxidant; Metal chelating

Indexed keywords

7,8 DEHYDRORUTAECARPINE DERIVATIVE; AMYLOID BETA PROTEIN; CURCUMIN; RUTAECARPINE; TROLOX C; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; IC 50; MOLECULAR MODEL; PROTEIN AGGREGATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; BIOCATALYSIS; BUTYRYLCHOLINESTERASE; CELL LINE, TUMOR; CELL SURVIVAL; CHELATING AGENTS; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLE ALKALOIDS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES;

EID: 84874942923     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.02.014     Document Type: Article

References (45)

1. D.M. Walsh, and D.J. Selkoe Deciphering the molecular basis of memory failure in Alzheimer's disease Neuron 44 2004 181 193
2. D.J. Selkoe, and M.B. Podlisny Deciphering the genetic basis of Alzheimer's disease Annu. Rev. Genomics Hum. Genet. 3 2002 67 99
3. A.V. Terry, and J.J. Buccafusco The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development J. Pharmacol. Exp. Ther. 306 2003 821 827
4. G. Pacheco, R. Palacios-Esquivel, and D.E. Moss Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase J. Pharmacol. Exp. Ther. 274 1995 767 770
5. D.R. Liston, J.A. Nielsen, A. Villalobos, D. Chapin, S.B. Jones, S.T. Hubbard, I.A. Shalaby, A. Ramirez, D. Nason, and W.F. White Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease Eur. J. Pharmacol. 486 2004 9 17
6. D.E. Kuhl, R.A. Koeppe, S.E. Snyder, S. Minoshima, K.A. Frey, and M.R. Kilbourn In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses Ann. Neurol. 59 2006 13 20
7. B.A. Yankner, L.R. Dawes, S. Fisher, L. Villa-Komaroff, M.L. Oster-Granite, and R.L. Neve Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease Science 245 1989 417 420
8. D.J. Selkoe Translating cell biology into therapeutic advances in Alzheimer's disease Nature 399 1999 A23 A31
9. E.D. Thorsett, and L.H. Latimer Therapeutic approaches to Alzheimer's disease Curr. Opin. Chem. Biol. 4 2000 377 382
10. G.P. Lim, T. Chu, F. Yang, W. Beech, S.A. Frautschy, and G.M. Cole The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse J. Neurosci. 21 2001 8370 8377
11. Y.E. Kwon, J.Y. Park, K.T. No, J.H. Shin, S.K. Lee, J.S. Eun, J.H. Yang, T.Y. Shin, D.K. Kim, B.S. Chae, J.Y. Leem, and K.H. Kim Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics Bioorg. Med. Chem. 15 2007 6596 6607
12. G. Colombo, I. Daidone, E. Gazit, A. Amadei, and A. Di Nola Molecular dynamics simulation of the aggregation of the core-recognition motif of the islet amyloid polypeptide in explicit water Proteins 59 2005 519 527
13. G.G. Tartaglia, A. Cavalli, R. Pellarin, and A. Caflisch The role of aromaticity, exposed surface, and dipole moment in determining protein aggregation rates Protein Sci. 13 2004 1939 1941
14. S. Verma, A. Singh, and A. Mishra The effect of fulvic acid on pre- and postaggregation state of Aβ(17-42): molecular dynamics simulation studies Biochim. Biophys. Acta 2012
15. Y. Porat, A. Abramowitz, and E. Gazit Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 67 2006 27 37
16. R. Scherzer-Attali, R. Pellarin, M. Convertino, A. Frydman-Marom, N. Egoz-Matia, S. Peled, M. Levy-Sakin, D.E. Shalev, A. Caflisch, E. Gazit, and D. Segal Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor PLoS ONE 5 2010 e11101
17. T.J. Gibson, and R.M. Murphy Design of peptidyl compounds that affect β-amyloid aggregation: importance of surface tension and context Biochemistry 44 2005 8898 8907
18. J.M. Mason, N. Kokkoni, K. Stott, and A.J. Doig Design strategies for anti-amyloid agents Curr. Opin. Struct. Biol. 13 2003 526 532
19. E. Brandenburg, H. von Berlepsch, U.I.M. Gerling, C. Böttcher, and B. Koksch Inhibition of amyloid aggregation by formation of helical assemblies Chem. Eur. J. 17 2011 10651 10661
20. M.L. Bolognesi, A. Cavalli, and C. Melchiorre Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease Neurotherapeutics 6 2009 152 162
21. M.L. Bolognesi, V. Andrisano, M. Bartolini, R. Banzi, and C. Melchiorre Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-β aggregation J. Med. Chem. 48 2004 24 27
22. N.C. Inestrosa, A. Alvarez, C.A. Pérez, R.D. Moreno, M. Vicente, C. Linker, O.I. Casanueva, C. Soto, and J. Garrido Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme Neuron 16 1996 881 891
23. M. Rosini, E. Simoni, M. Bartolini, A. Cavalli, L. Ceccarini, N. Pascu, D.W. McClymont, A. Tarozzi, M.L. Bolognesi, A. Minarini, V. Tumiatti, V. Andrisano, I.R. Mellor, and C. Melchiorre Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush J. Med. Chem. 51 2008 4381 4384
24. P. Camps, X. Formosa, C. Galdeano, T.n. Gomez, D. Munoz-Torrero, M. Scarpellini, E. Viayna, A. Badia, M.V.r. Clos, A. Camins, M. Pallas, M. Bartolini, F. Mancini, V. Andrisano, J. Estelrich, M. Lizondo, A. Bidon-Chanal, and F.J. Luque Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation J. Med. Chem. 51 2008 3588 3598
25. M.A. Ansari, and S.W. Scheff Oxidative stress in the progression of Alzheimer disease in the frontal cortex J. Neuropathol. Exp. Neurol. 69 2010 155 167
26. V.P. Reddy, X. Zhu, G. Perry, and M.A. Smith Oxidative stress in diabetes and Alzheimer's disease J. Alzheimer's Dis. 16 2009 763 774
27. F. Gu, M. Zhu, J. Shi, Y. Hu, and Z. Zhao Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice Neurosci. Lett. 440 2008 44 48
28. X. Huang, R.D. Moir, R.E. Tanzi, A.I. Bush, and J.T. Rogers Redox-active metals, oxidative stress, and Alzheimer's disease pathology Ann. N. Y. Acad. Sci. 1012 2004 153 163
29. D.R.C. McLachlan, T.P.A. Kruck, W. Kalow, D.F. Andrews, A.J. Dalton, M.Y. Bell, and W.L. Smith Intramuscular desferrioxamine in patients with Alzheimer's disease Lancet 337 1991 1304 1308
30. C.W. Ritchie Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch. Neurol. 60 2003 1685 1691
31. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, J. Harrison, C.L. Masters, S. Targum, A.I. Bush, R. Murdoch, J. Wilson, and C.W. Ritchie Safety, efficacy, and biomarker findings of PBT2 in targeting A? As a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 7 2008 779 786
32. A.I. Bush Drug development based on the metals hypothesis of Alzheimer's disease J. Alzheimer's Dis. 15 2008 223 240
33. A. Cavalli, M.L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini, and C. Melchiorre Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 51 2008 347 372
34. B. Wang, Y.-C. Mai, Y. Li, J.-Q. Hou, S.-L. Huang, T.-M. Ou, J.-H. Tan, L.-K. An, D. Li, L.-Q. Gu, and Z.-S. Huang Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors Eur. J. Med. Chem. 45 2010 1415 1423
35. W. Yang, Y. Wong, O.T.W. Ng, L.-P. Bai, D.W.J. Kwong, Y. Ke, Z.-H. Jiang, H.-W. Li, K.K.L. Yung, and M.S. Wong Inhibition of beta-amyloid peptide aggregation by multifunctional carbazole-based fluorophores Angew. Chem. Int. Ed. 51 2012 1804 1810
36. Y.-Z. Tang, and Z.-Q. Liu Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes Bioorg. Med. Chem. 15 2007 1903 1913
37. J. Bergman, and S. Bergman Studies of rutaecarpine and related quinazolinocarboline alkaloids J. Org. Chem. 50 1985 1246 1255
38. G.L. Ellman, K.D. Courtney, V. Andres Jr., and R.M. Feather-Stone A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88 95
39. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 19 1998 1639 1662
40. P. Deb, A. Sharma, P. Piplani, and R. Akkinepally Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors Mol. Divers. 16 2012 803 823
41. M. Bartolini, C. Bertucci, M.L. Bolognesi, A. Cavalli, C. Melchiorre, and V. Andrisano Insight into the kinetic of amyloid β (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action ChemBioChem 8 2007 2152 2161
42. P. Kapková, V. Alptüzün, P. Frey, E. Erciyas, and U. Holzgrabe Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Aβ fibril formation inhibition capacity Bioorg. Med. Chem. 14 2006 472 478
43. M.L. Bolognesi, A. Cavalli, L. Valgimigli, M. Bartolini, M. Rosini, V. Andrisano, M. Recanatini, and C. Melchiorre Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease J. Med. Chem. 50 2007 6446 6449
44. B. Ou, M. Hampsch-Woodill, and R.L. Prior Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe J. Agric. Food Chem. 49 2001 4619 4626
45. A. Dávalos, C. Gómez-Cordovés, and B. Bartolomé Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay J. Agric. Food Chem. 52 2003 48 54